Floatz logo

Daunorubicin

Secondary Acute Myeloid Leukemia

National Cancer Institute (NCI)Phase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
81/ 100

Competitive context

78 Active assets in the Secondary Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →